Home   >  
∨

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Angiogenesis/Protein Tyrosine Kinase

Chemical Structure Cat. No. Product Name CAS No.
Mutated EGFR-IN-1 Chemical Structure
 BCP28639 Mutated EGFR-IN-1 1421372-66-8
Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.
Sevabertinib Chemical Structure
 BCP49699 Sevabertinib 2521285-05-0
Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity.
AST5902 mesylate Chemical Structure
 BCP49683 AST5902 mesylate 2412155-75-8
AST5902 mesylate is principal metabolite of Alflutinib in vivo.
Sunitinib Chemical Structure
 BCP02336 Sunitinib 557795-19-4
Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
QL-1200186 Chemical Structure
 BCP49631 QL-1200186 2848664-42-4
QL-1200186 is an orally active and selective TYK2 inhibitor.
Befotertinib Chemical Structure
 BCP49575 Befotertinib 1835667-63-4
Befotertinib is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).
Efruxifermin Chemical Structure
 BCP49432 Efruxifermin 2375240-92-7
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21).
OPT-302 Chemical Structure
 BCP49401 OPT-302 OPT-302
OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D.
Batiraxcept Chemical Structure
 BCP49357 Batiraxcept 2268717-61-7
Batiraxcept is an ultra-high affinity decoy protein that captures GAS6, preventing it from activating AXL signaling.
APS-03118 Chemical Structure
 BCP49314 APS-03118 APS-03118
APS03118 is a novel next-generation RET inhibitor which is potent against a range of RET fusions and mutations including both SFMs and gatekeeper mutations.
123下一页末页共 897 条记录 1 / 90 页 
0086-13720134139